Ironwood Pharmaceuticals is trading at $3.81, up 5.10%, with no confirmed company-specific announcement or report explaining the October 7 session gain. - Recent coverage discusses raised 2026 guidance and second-quarter results, but no new catalyst for this session. - Biotech stocks and the broader market are lower; neither clearly explains Ironwood Pharmaceuticals’ rise. - Intraday volume was unavailable in the supplied price data and search results.